Research and Markets (http://www.researchandmarkets.com/research/vmxlcw/sicca_syndrome) has announced the addition of the "Sicca Syndrome (Sjogren) - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Sicca Syndrome (Sjogren) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sicca Syndrome (Sjogren) Prostate Cancer and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Sicca Syndrome (Sjogren) Prostate Cancer Overview
- Therapeutics Development
- Pipeline Products for Sicca Syndrome (Sjogren) Prostate Cancer - Overview
- Pipeline Products for Sicca Syndrome (Sjogren) Prostate Cancer - Comparative Analysis
- Sicca Syndrome (Sjogren) Prostate Cancer - Therapeutics under Development by Companies
- Sicca Syndrome (Sjogren) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes
- Sicca Syndrome (Sjogren) Prostate Cancer - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Sicca Syndrome (Sjogren) Prostate Cancer - Products under Development by Companies
- Sicca Syndrome (Sjogren) Prostate Cancer - Products under Investigation by Universities/Institutes
- Sicca Syndrome (Sjogren) Prostate Cancer - Companies Involved in Therapeutics Development
- Akari Therapeutics, Plc
- Amgen Inc.
- Ampio Pharmaceuticals, Inc.
- Biogen, Inc.
- Bristol-Myers Squibb Company
- GlaxoSmithKline Plc
- MedImmune, LLC
- Novartis AG
- Redx Pharma Plc
- Toleranzia AB
- UCB S.A.
For more information visit http://www.researchandmarkets.com/research/vmxlcw/sicca_syndrome
View source version on businesswire.com: http://www.businesswire.com/news/home/20160208005622/en/
Contacts:
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune
Disorders
